Specific alkylation of human telomere repeats by hairpin pyrrole-imidazole polyamide

Bioorganic and Medicinal Chemistry

Volumn 11, Issue 12, 2003, Pages 2503-2509

  Takahashi, Ryoko ^a   Bando, Toshikazu ^a   Sugiyama, Hiroshi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; DNA FRAGMENT; IMIDAZOLE DERIVATIVE; PEPLEOMYCIN; POLYAMIDE; PYRROLE DERIVATIVE;

ALKYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CONJUGATE; CONTROLLED STUDY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; POLYACRYLAMIDE GEL ELECTROPHORESIS; TANDEM REPEAT; TELOMERE;

EID: 0037997124     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(03)00176-7     Document Type: Article

References (19)

1. Martens U.M. Nat. Genet. 18:1998;76.
2. Blackburn E.H. Annu. Rev. Biochem. 61:1992;113.
3. (a) Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L.C., Coviello G.M., Wright W.E., Weinrich S.L., Shay J.W. Science. 266:1994;2011;
4. (b) Counter C.M., Hirte H.W., Bachetti S., Harley C.B. Proc. Natl. Acad. Sci. U.S.A. 91:1994;2900.
5. (b) Hurley L.H. Nat. Rev. Cancer. 2:2002;188.
6. (a) Herbert B.-S., Pitts A.E., Baker S.I., Hamilton S.E., Wright W.E., Shay J.W., Corey D.R. Proc. Natl. Acad. Sci. U.S.A. 96:1999;14276;
7. Pelton J.G., Wemmer D.E. Proc. Natl. Acad. Sci. U.S.A. 86:1989;5723.
8. White S., Baird E.E., Dervan P.B. Chem. Biol. 4:1997;569.
9. Tao Z.-F., Fujiwara T., Saito I., Sugiyama H. J. Am. Chem. Soc. 121:1999;4961.
10. Bando T., Narita A., Saito I., Sugiyama H. Chem. Eur. J. 8:2002;4781.
11. Nagamura S., Asai A., Kanda Y., Kobayashi E., Gomi K., Saito H. Chem. Pharm. Bull. 44:1996;1723.
12. Swalley S.E., Baird E.E., Dervan P.B. J. Am. Chem. Soc. 119:1997;6953.
13. Yamori T., Matsunaga A., Sato S., Yamazaki K., Komi A., Ishizu K., Mita I., Edatsugi H., matsuba Y., Takezawa K., Nakanishi O., Kohno H., Nakajima Y., Komatsu H., Andoh T., Tsuruo T. Cancer Res. 59:1999;4042.
14. (a) Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., Hose C., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrichi M., Campbell H., Mayo J., Boyd M. J. Natl. Cancer Inst. 83:1991;757;
15. (b) Yamori T., Sato S., Chikazawa H., Kadota T. Jpn. J. Cancer Res. 88:1997;1205.
16. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., Boyd M.R. J. Natl. Cancer Inst. 82:1990;1107.
17. (a) Boyd, M. R. Status of the National Cancer Institute Preclinical Antitumor Drug Discovery Screen: Implications For Clinical Trial. In: V. T. Devita, Jr., S. Hellman, S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology Update, Vol. 3, p 1-12. Philadelphia: Lippincott, 1989;
18. (b) Paull K.D., Shoemaker R.H., Hodes L., Monks A., Scudiero D.A., Rubinstein L., Plowman J., Boyd M.R. J. Natl. Cancer Inst. 81:1989;1088.
19. Maxam A.M., Gilbert W. Proc. Natl. Acad. Sci. U.S.A. 74:1977;560.